# PACE-B

Source: https://onco.cc/trials/pace-b/  
OnCo record `pace-b` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PACE-B showed that five stereotactic treatments control low- and intermediate-risk prostate cancer as well as four to eight weeks of conventional radiotherapy, with similar side effects at five years.

## Summary

PACE-B randomised 874 men to stereotactic body radiotherapy (36.25 Gy in five fractions over one to two weeks) or conventional radiotherapy (78 Gy in 39 or 62 Gy in 20 fractions), without hormone therapy. Five-year freedom from biochemical or clinical failure was 95.8 percent with SBRT and 94.6 percent with conventional treatment, meeting non-inferiority; genitourinary toxicity of grade 2 or worse was somewhat higher after SBRT (van As and colleagues, New England Journal of Medicine 2024). Five-fraction treatment is now a standard option.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-16
- Tags: radiation-wave2
- Registry id: NCT01584258
- Phase: 3
- Setting: Low- and intermediate-risk prostate cancer: stereotactic body radiotherapy in five fractions versus conventional or moderately hypofractionated radiotherapy
- Sponsor: Royal Marsden NHS Foundation Trust
- Enrolled: 874
- Result: 5-year biochemical or clinical failure-free 95.8% (SBRT) vs 94.6% (conventional), non-inferior.
- Outcomes: Freedom from biochemical or clinical failure at 5 years: SBRT 36.25 Gy in 5 95.8% vs Conventional radiotherapy 94.6%

## Sources

- ClinicalTrials.gov NCT01584258: https://clinicaltrials.gov/study/NCT01584258
- NEJM 2024: https://doi.org/10.1056/NEJMoa2403365

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Hypofractionated radiotherapy](https://onco.cc/technologies/hypofractionated-radiotherapy/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)

---
JSON: https://onco.cc/api/v1/entities/pace-b.json